EDEvren Odyakmaz Demirsoy

Evren Odyakmaz Demirsoy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evren Odyakmaz Demirsoy has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early‐Stage Mycosis Fungoides: A Single‐Center Retrospective Real‐World Study

    by Fatich Memet, Dilek Bayramgürler, Abdullah Demirbaş, Evren Odyakmaz Demirsoy, Aysun Şikar Aktürk, Nilgün Sayman, Rebiay Kıran

    Topical bexarotene 1% gel is an approved skin‐directed treatment for refractory or persistent stage IA‐IB cutaneous T‐cell lymphoma, but real‐world evidence in mycosis fungoides (MF), particularly regarding maintenance use after complete response, remains limited. We retrospectively reviewed 56 patients with histopathologically and immunohistochemically confirmed, previously treated stage IA‐IB MF who received topical bexarotene between 2009 and 2022. Clinical response, post‐treatment biopsy findings, adverse events, maintenance therapy, and relapse outcomes were analyzed. The cohort included 31 women and 25 men; 42 patients (75.0%) had stage IA and 14 (25.0%) had stage IB disease. Complete response (CR) was achieved in 20 patients (35.7%) and partial response in 15 (26.8%), yielding an overall response rate of 62.5%. Overall response was higher in stage IA than in stage IB disease (73.8% vs. 28.6%; p = 0.003) and in T1a than in T2a disease (77.1% vs. 36.4%; p = 0.044). All biopsied complete responders showed no MF‐compatible histology. Adverse events were exclusively local and manageable. Among 18 evaluable complete responders, relapse occurred in 15 (83.3%). Median time to relapse was longer with maintenance topical bexarotene than without maintenance (45 vs. 30 weeks; p = 0.039). Topical bexarotene appears effective and well tolerated in previously treated stage IA‐IB MF, with greatest benefit in limited patch‐stage disease. Maintenance use after CR may delay relapse, but this exploratory finding requires prospective validation.

  • Selective Involvement of Photoprotected Skin in an IL ‐36‐Driven Pustular Eruption: A Possible Reverse Recall Phenomenon

    by Evren Odyakmaz Demirsoy, Semanur Çakır Serinbaş, Dilek Bayramgürler, Busra Yaprak Bayrak, Rebiay Kıran

  • Efficacy of pro-yellow laser versus cryotherapy in treating cutaneous lesions of Kaposi’s sarcoma: a comparative study

    by Selin İlChan, Dilek Bayramgürler, Abdullah Demirbaş, Evren Odyakmaz Demirsoy, Aysun Şikar Aktürk, Rebiay Kıran, Nilgün Sayman

    This study aimed to evaluate the efficacy of Pro-Yellow Laser (PYL) in treating plaque and patch lesions of classical Kaposi’s Sarcoma (KS) and compare its outcomes with cryotherapy (CT). A single-blind, randomized, comparative experimental study was conducted on nine HIV-negative classical KS patients at Kocaeli University Dermatology Outpatient Clinic between April 2022 and April 2023. Each patient received both CT and PYL treatments on separate lesions. Lesions were scored based on surface area and depth before and after treatment, and percentage change (PC) was calculated. A total of 41 lesions were treated (16 with CT and 25 with PYL). CT achieved 100% median PC, while PYL showed a median PC of 42.58% (p = 0.008). No significant difference was observed between CT and PYL in macule/patch lesions (DS-1, p = 0.192), but CT was significantly more effective for papule/plaque lesions (DS-2, p = 0.048). CT caused minor side effects such as blistering and delayed healing, while PYL was well-tolerated with no adverse events. PYL demonstrated comparable efficacy to CT for early-stage KS lesions with fewer complications, making it a promising alternative for patients unable to tolerate CT. However, CT remains more effective for advanced lesions. Further studies are needed to confirm these findings in larger cohorts.


  • Open Access

    Análise das características clínicas e fatores que afetam a resposta ao tratamento em pacientes com pioderma gangrenoso: estudo multicêntrico com 239 pacientes

    by Funda Erduran, Esra Adışen, Yıldız Hayran, Güneş Gür Aksoy, Erkan Alpsoy, Leyla Baykal Selçuk, Sibel Doğan Günaydın, Ayça Cordan Yazıcı, Ayşe Öktem, Malik Güngör, et al.

  • Open Access

    Analysis of clinical characteristics and factors affecting treatment responses in patients with pyoderma gangrenosum: a multicenter study of 239 patients☆

    by Funda Erduran, Esra Adışen, Yıldız Hayran, Güneş Gür Aksoy, Erkan Alpsoy, Leyla Baykal Selçuk, Sibel Doğan Günaydın, Ayça Cordan Yazıcı, Ayşe Öktem, Malik Güngör, et al.


  • Şeyletiella Dermatiti: Olgu Sunumu

    by Aysun Şi̇kAr Aktürk, Cansu Alakbarov, Ayşe TOPÇU, Evren Odyakmaz

    Şeyletiella dermatiti (şeyletielloz); ana rezervuarı kedi, köpek ve tavşanlar olan Cheyletiella cinsi parazitlerin rastlantısal olarak insana bulaşması sonucu oluşan bir dermatit tablosudur. Hayvanların birbirleriyle ve dış ortamla temasının arttığı bahar aylarında sık görülür. Şeyletiella dermatiti hayvanla temastan ortalama 1-2 gün sonra ortaya çıkan sıklıkla eritemli ödemli papüllerle karakterizedir. Nadiren vezikülobüllöz ve nekrotizan lezyonlar da oluşabilir. Evcil hayvan taşıyıcı olduğu için insanla her temasdan sonra lezyonlar tekrarlayabilir. Lezyonlar dışında deride parazitin kendisi de nadiren görülebilmektedir. Ancak klinik olarak şüphelenilmediği takdirde tanı konulması zordur. Burada elli sekiz yaşında şeyletiella dermatiti tanısı konulan bir kadın hasta sunulmaktadır. Tekrarlayan kaşıntılı döküntü şikayeti ve özellikle kedi olmak üzere evcil hayvan yetiştirme öyküsü olan kişilerde ayırıcı tanıda şeyletiella dermatitinin de düşünülmesi gerektiğini vurgulamak için olgumuz sunulmuştur.

  • What is your Diagnosis?

    by Evren Odyakmaz Demirsoy, Cengiz Erçin, Mehmet Kılıç, Nilgün Sayman

  • Imiquimod 5% Cream Versus Cryotherapy in Classic Kaposi Sarcoma

    by Evren Odyakmaz Demirsoy, Dilek Bayramgürler, Çiğdem Çağlayan, Nilgün Bilen, Aysun Şikar Aktürk, Rebiay Kıran

    Background: Classic Kaposi sarcoma usually remains on the skin and has a slow progression; thus, local treatment methods are preferable. Imiquimod is an immunomodulatory agent with antiviral, antitumoural, and antiangiogenic properties that is expedient against Kaposi sarcoma. Objectives: We aimed to clarify whether imiquimod is effective on classic Kaposi sarcoma lesions by comparing imiquimod treatment with cryotherapy, which is the most-used treatment method in our department for this disease. Method: Patients with classic Kaposi sarcoma were included. All lesions of each patient were evaluated and measured by the blinded investigator considering infiltration and surface diameters. Then, lesions were categorized into 2 groups by the other investigator (nonblinded), and imiquimod 5% cream was administered 3 times per week without occlusion in 1 group. Cryotherapy was performed every 3 weeks in the other group. All lesions were reevaluated and measured at the end of 12 weeks by the blinded investigator. Initial and last measurements were compared between the treatment methods. Results: Fifty lesions of 8 patients were included in this study. Imiquimod and cryotherapy were applied to 26 and 24 lesions, respectively. At the end of the study, statistically significant decreases were detected in all scores between weeks 0 and 12 with both treatment methods. Mean percentages of change in scores were not significantly different between the methods. Conclusions: Based on a limited number of patients and lesions treated, we believe imiquimod may be a suitable option to use for the treatment of classic Kaposi sarcoma.


  • Contact sensitivity to textile dyes in patients with pigmented purpuric dermatosis

    by Irem Ozturk Ozcan, Evren Odyakmaz Demirsoy, Nilgün Sayman, Aysun Sikar Akturk, Dilek Bayramgurler, Rebiay Kiran

    Purpose: The etiology of pigmented purpuric dermatoses is unclear. Recent studies speculate about contact sensitivity to play a role in the etiology of the disease. In most patients, the lesions begin and stay limited on the lower extremities as textile products are in tight contact with the skin. Also, textile dyes can cause contact dermatitis of purpuric type. This study was conducted in order to understand whether the contact sensitivity plays a critical role in the etiology of pigmented purpuric dermatoses. Materials and Methods: Patients with diagnosis of pigmented purpuric dermatoses were included in the study. Patch tests were applied at the back of all patients with textile series (Chemotechnique Diagnostics TF-1000) which have 33 allergens containing textile dyes, material and protectors by IQ Ultra Chamber. Test sites were evaluated at 48, 72, 96. hours and on the 7th day according to the criteria of the International Contact Dermatitis Research Group. The evaluation results were recorded in patient files and the results were statistically compared. Results: Eighteen males (60%) and 12 females (40%), a total of 30 patients were included in the study. Schamberg disease in 23 patients (76.7%), lichen aureus in 5 patients (16.7%) and Majocchi disease in 2 patients (6.7%) were described out of total 30 patients. No contact sensitivity was detected in any of the patients. Conclusion: Contact sensitivity to textile dyes was not found as an etiologic factor in our study group.

  • Eosinophilic pustular folliculitis of infancy suppressed with cetirizine

    by Evren Odyakmaz Demirsoy, Uğur Demirsoy, Umay Ozod, Rebiay Kiran

    Eosinophilic pustular folliculitis of infancy is a rare inflammatory disease characterized by recurrent, itchy sterile pustules mainly located on the scalp. Topical agents are mostly effective to suppress the symptoms in the majority of cases. However, systemic agents that are safe for long‐term use are required for patients with widespread or resistant lesions. We present a case with eosinophilic pustular folliculitis of infancy whose disease was suppressed with cetirizine but recurred after ceasing the drug.